1. Home
  2. TII vs VYGR Comparison

TII vs VYGR Comparison

Compare TII & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TII

Titan Mining Corporation

N/A

Current Price

$3.95

Market Cap

231.0M

Sector

N/A

ML Signal

N/A

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.69

Market Cap

222.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TII
VYGR
Founded
2012
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.0M
222.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TII
VYGR
Price
$3.95
$3.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$6.25
$17.00
AVG Volume (30 Days)
1.5M
745.6K
Earning Date
03-20-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$75,461,000.00
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.77
P/E Ratio
$30.14
N/A
Revenue Growth
54.36
N/A
52 Week Low
$0.26
$2.65
52 Week High
$5.65
$5.73

Technical Indicators

Market Signals
Indicator
TII
VYGR
Relative Strength Index (RSI) 49.18 38.11
Support Level $3.62 $3.51
Resistance Level $4.66 $4.09
Average True Range (ATR) 0.50 0.24
MACD -0.14 -0.03
Stochastic Oscillator 8.87 11.89

Price Performance

Historical Comparison
TII
VYGR

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: